glp-1

Semaglutide, sold as Ozempic and Wegovy, and tirzepatide, sold as Zepbound and Mounjaro, are new therapies for weight loss that actually work, helping millions around the world to feel better. But some people are fearful of side effects, such as loss of muscle mass. Are their fears warranted...

* Dr. le Roux shares exclusive insights into the Phase 3 data for #Survodutide (Boehringer Ingelheim’s dual GLP-1/glucagon agonist), including its groundbreaking impact on visceral fat and #FattyLiverDisease (MASLD/MASH) via the SYNCHRONIZE trials. In this #DoctorPodcasts Episode 149, we...

Truly impressive! * the really exciting data of SYNCHRONIZE-1 was not the weight loss it was actually the metabolic health gains so we see that there was an improvement in glycemia and blood pressure but there was a. 63% REDUCTION IN FAT IN THE LIVER so imagine you had 16% weight loss but 25%...

Carel le Roux is a Professor of Experimental Pathology at University College Dublin, Director of the Metabolic Medicine Group, and one of the world's leading researchers on how the gut communicates with the brain. He completed his PhD at Imperial College London, where he conducted foundational...

Nature staff discuss preliminary data on the effects of GLP-1 drugs on male fertility, plus a two-year trial of a brain-computer interface. Timestamps 00:18 Brain-computer interface makes a life-changing impactNature: At-home brain implant gives man with motor neuron disease his daily life...

Dr. Andres Guillen Lozoya discusses findings from, "Testosterone Levels Improve in Men under GLP-1 Receptor Agonist Therapy.” This study aimed to evaluate changes in total and free testosterone before and after GLP-1RA therapy in men

In this episode of Science Quickly, Scientific American’s associate health editor Lauren Young joins host Kendra Pierre-Louis to talk about how the story of GLP‑1 drugs such as Ozempic, Wegovy and Mounjaro is evolving. We trace GLP-1s’ origins as type 2 diabetes treatments, their rise as...

Are GLP-1 agonists like Ozempic and Mounjaro the future of healthcare or a risk to your health? We break down the latest data on weight loss medication efficacy, common side effects, and the truth about muscle mass loss (sarcopenia). In This Episode: Dr. Jordan Feigenbaum and Dr. Austin...

In this video, David Kerr, MD examines the complex relationship between GLP-1 receptor agonists and gastrointestinal health. While these agents are highly effective for treating type 2 diabetes and obesity, a large-scale meta-analysis of over five million individuals suggests a nuanced...

Amy M. Pearlman, MD, Co-Founder, Prime Institute, Coral Gables, Florida, discusses the evolving role of testosterone. She centers the intersection of testosterone therapy and glucagon-like peptide-1 (GLP-1) medications, highlighting clinical considerations increasingly relevant to urology...

* we discuss what a recently rolled-out GLP-1 pill, the first of its kind approved for obesity, could mean for the future of weight loss. Drugs known as glucagon-like peptide-1 receptor agonists, colloquially called GLP-1 medications, have gone from relatively obscure diabetes...

In this episode, Dr. Spencer Nadolsky discusses the transformative role of GLP-1 medications in obesity treatment. He explains the mechanism of GLP-1, its rise in popularity, associated risks, and the importance of personalized medicine. The conversation also touches on the significance of...

*This discussion explores why libido is frequently ignored and how it differs from arousal, performance, orgasm, and ejaculation. It highlights the brain as the primary sexual organ and explains how psychological factors such as stress, anxiety, depression, and chronic fatigue can significantly...

New drug candidates could transform the obesity treatment landscape again, as pill formulations and multi-agonist treatments undergo clinical trials. Endocrine Society experts Priya Jaisinghani, MD, DABOM, and Mehmet Furkan Burak, MD, discussed how emerging treatments could improve obesity...

Figure 1. Comparative overview of therapeutic approaches for male hypogonadism and metabolic dysfunction. The figure summarizes the key advantages and disadvantages of three main management modalities: GLP-1 receptor agonists (GLP-1 RAs), lifestyle modification (diet and exercise), and...

I have not had very good experiences with GLP-1 drugs. The appetite suppression was nice, but the gastrointestinal side effects were a deal breaker. Semaglutide and Tirzepatide both shut down my digestive system. My wife has been on Retatrutide for a few months with very good results. I need to...

Takeaway Messages

Newly joined member here but have been lurking for 6mo learning and absorbing as much as I can here. Appreciate what an incredible resource this site is and the members contributing. I fell into the trap of eating poorly, drinking often, and spiraling my weight out of control in the last few...

In this episode of On the Edge of Breakthrough, host Dr. Monty Pal sits down with Dr. Charles Brenner, an internationally recognized expert in metabolism and the founding Chair of the Department of Diabetes & Cancer Metabolism at City of Hope. Together, they explore the metabolic links between...

* Among the human studies, 9 evaluated testosterone levels (total and/or free), 6 reported on gonadotropins (LH, FSH), and 5 assessed clinical hypogonadal symptoms such as libido and erectile function. In total, 7 human studies demonstrated a statistically significant increase in testosterone...

https://diabetesjournals.org/diabetes/article/74/Supplement_1/1966-LB/158768/1966-LB-Efficacy-and-Safety-of-Semaglutide-7-2-mg Introduction https://sciencehub.novonordisk.com/congresses/ada2025/Lingvay.html

In this episode of You Are Not Broken, Dr. Kelly Casperson sits down with endocrinologist and obesity medicine expert Dr. Rocio Salas-Whalen for a deep dive into GLP-1 medications (like Ozempic, Wegovy, and Mounjaro). They cover everything you should be asking but probably haven’t heard...

https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.16612 Abstract Aims Nearly 42% of adults in the United States have obesity, a significant risk factor for many cardiometabolic diseases and cancers. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are promising...

This article outlines a comprehensive strategy for optimizing fat loss and muscle preservation, primarily discussed within the context of an online forum dedicated to men's health, ExcelMale.com. The core of the strategy involves a multi-faceted approach combining specific pharmacotherapies...

GLP-1 receptor agonists are revolutionizing treatment for diabetes and obesity, but their impact on the gastrointestinal tract demands careful clinical attention. Dr. Peter Buch is joined by Dr. Michael Camilleri, Professor of Medicine at the Mayo Foundation for Medical Education and Research in...

* Given emerging data on sarcopenia and GLP-1 RAs, future studies should investigate the potential role of combined GLP-1 and testosterone therapies to optimize outcomes in body composition, metabolic control, and sexual health. Table 1. Impact of GLP-1 Receptor Agonist Therapy on...

In todays Wall Street Journal an interesting read about weight loss drugs and sports performance.............. https://www.wsj.com/health/wellness/ozempic-amateur-athletes-3fc9e0bf?st=jgBnBU&reflink=article_email_share

https://www.urologytimes.com/view/pearls-perspectives-urology-role-in-glp-1-ra-treatments-with-hossein-sadeghi-nejad-md-and-nathalie-eid-ba In this 2-part episode of Pearls and Perspectives from the American Urological Association's (AUA) 2025 Annual Meeting in Las Vegas, NV, host Amy Pearlman...

https://www.cnbc.com/2025/04/25/novo-nordisk-legal-win-bars-many-compounded-wegovy-ozempic-drugs.html Key Points Novo Nordisk scored a huge legal victory that largely restricts compounding pharmacies from marketing or selling cheaper, unapproved versions of the drugmaker’s blockbuster weight...

The guest speakers says it all LOL! The Obesity Society (TOS) convened a panel of leading experts in obesity medicine, pharmacy, and regulatory law on March 19, 2025, to discuss the growing concerns surrounding the use of compounded GLP-1s for weight management and diabetes treatment. The...

In this episode, Dr. Rena Malik, MD, and Dr. Alexandra Sowa dive into the transformative effects of new obesity medications, highlighting dramatic weight loss results and their profound impact on personal and romantic relationships. They explore both the psychological and social dimensions...